RVX.TO - Resverlogix Corp.

Toronto - Toronto Delayed Price. Currency in CAD
1.4100
-0.0800 (-5.37%)
As of 9:47AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.4900
Open1.4100
Bid1.4200 x 0
Ask1.4600 x 0
Day's Range1.4000 - 1.4500
52 Week Range0.3500 - 4.9400
Volume10,932
Avg. Volume262,040
Market Cap294.907M
Beta (3Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.5620
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.53
  • GlobeNewswire

    Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019

    Apabetalone treatment improves cognition in CVD patients with diabetes Subsequent conference call & webcast scheduled to present BETonMACE prespecified cognition assessment.

  • GlobeNewswire

    Resverlogix Announces Warrant Exercise Incentive Program

    CALGARY, Alberta, Nov. 25, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) announces a warrant exercise incentive program (“Incentive Program”) designed.

  • GlobeNewswire

    Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019

    CALGARY, Alberta, Nov. 12, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to.

  • RVX.TO: Some Clarity on the Path Forward
    Zacks Small Cap Research

    RVX.TO: Some Clarity on the Path Forward

    By John Vandermosten TSX:RVX.TO During Resverlogix’ (TSX:RVX.TO) Annual Meeting of Shareholders on October 31st, the company shared milestones expected over the next few months. Key events include further consultation with the FDA and presentation of the full data set at conferences and to investors. Not much detail has been provided over the last month following the topline announcement for the

  • GlobeNewswire

    Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders

    CALGARY, Alberta, Oct. 31, 2019 -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary,.

  • GlobeNewswire

    Zenith Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Oct. 31, 2019 -- Zenith Capital Corp. ("Zenith" or the "Company") announces that, at its annual and special meeting of shareholders held earlier today, Zenith.

  • GlobeNewswire

    Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) announces that BETonMACE did not meet the primary endpoint – reduction in major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction and stroke – added to standard of care in high-risk patients with type 2 diabetes, recent acute coronary syndrome, and low HDL cholesterol. Apabetalone demonstrated tolerability and safety.

  • GlobeNewswire

    Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announces that it has issued a 10% secured convertible debenture in the principal amount of US$12 million (the “Debenture”) to a wholly-owned subsidiary of ORI Star Fund LP (“ORI” or the “Fund”). The Debenture bears interest at a rate of 10% per annum and matures on September 26, 2020. The Fund may elect to convert the Debenture into common shares of the Company at a conversion price equal to the lesser of CAD$2.54 per share and the 5-day volume weighted average trading price of the common shares on the date of conversion.

  • GlobeNewswire

    Resverlogix to Host BETonMACE Webcast and Conference Call

    CALGARY, Alberta, Sept. 26, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that, in connection with BETonMACE topline results, expected.

  • CNW Group

    Toronto Stock Exchange Introduces the TSX30

    Toronto Stock Exchange Introduces the TSX30

  • GlobeNewswire

    Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019

    CALGARY, Alberta, Sept. 23, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today the Late Breaking Science submission, regarding the primary.

  • GlobeNewswire

    Resverlogix Provides Update on BETonMACE Phase 3 Trial

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) announced today that, following the completion of final patient safety visits (as reported by the Company on July 8, 2019), the resolution of all outstanding queries is expected within a matter of days, leading to database lock. Furthermore, it is projected that the number of narrowly-defined Major Adverse Cardiovascular Events (“MACE”) – defined as a single composite endpoint of cardiovascular death or non-fatal myocardial infarction or stroke – to be used in the primary data analysis, is now estimated to be greater than 275 – compared to the initial calculation of 250 events in the trial’s protocol.

  • GlobeNewswire

    Resverlogix Announces Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Aug. 22, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that its Annual and Special Meeting of Shareholders (the.

  • GlobeNewswire

    Zenith Announces Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Aug. 22, 2019 -- Zenith Capital Corp. (“Zenith”) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”) is to be held Thursday,.

  • GlobeNewswire

    Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019

    CALGARY, Alberta, Aug. 14, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announces today that it will present at ESC Congress 2019, held this year in.

  • GlobeNewswire

    Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

    Zenith Capital Corp. (“Zenith”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics” or the “Company”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara BioPharma Co., Ltd. (“Newsoara”) for the Company’s lead compound, ZEN-3694, in China, Hong Kong, Taiwan, and Macau (the “Territories”). Under the terms of the agreement, Newsoara will have the rights to develop, market, and distribute ZEN-3694 for all indications in the Territories.

  • GlobeNewswire

    Resverlogix Announces Loan Reduction and Extension

    CALGARY, Alberta, Aug. 02, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an amending agreement with Third Eye.

  • GlobeNewswire

    Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today the recent publication of an article titled: “Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism” in Clinical Epigenetics, a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment.

  • GlobeNewswire

    Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits

    CALGARY, Alberta, July 08, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the.

  • GlobeNewswire

    Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

    Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the first patient in a Phase 1b/2 clinical trial undertaken in collaboration with Pfizer Inc. (“Pfizer”). The trial will evaluate the combination, safety and efficacy of the Company’s ZEN-3694, a novel and differentiated bromodomain and extra-terminal domain inhibitor (“BETi”), and Pfizer’s talazoparib, a poly ADP ribose polymerase inhibitor (“PARPi”), in patients with locally advanced or metastatic triple negative breast cancer without germline BRCA1/2 mutations. Preclinical data indicate that combining talazoparib with ZEN-3694 is a rational combination to test in patients that are proficient in homologous DNA repair.

  • GlobeNewswire

    Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) is pleased to announce today that all patients active in BETonMACE, the Company’s event-based, phase 3 registration trial, recently completed their last study visits on treatment. Once safety visits have concluded for all patients, Resverlogix anticipates being in a position to provide an updated projected timeframe for top-line data readout.

  • GlobeNewswire

    Resverlogix Announces Participation at Leading, International Scientific Conferences

    CALGARY, Alberta, June 10, 2019 -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading, international scientific.

  • GlobeNewswire

    Resverlogix Announces Closing of $15 Million Offering

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) is pleased to announce today that it has closed its previously announced offering (the “Offering”) of units of the Company (the “Units”). Each warrant is exercisable at a price of $4.60 per underlying common share for a period of 4 years from the closing of the Offering.

  • CNW Group

    IIROC Trade Resumption - RVX

    IIROC Trade Resumption - RVX

  • GlobeNewswire

    Resverlogix Announces Pricing of Unit Offering

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO)  is pleased to announce today that it has priced its previously announced marketed offering (the “Offering”) of units of the Company (the “Units”) at $4.00 per Unit.  Each Unit consists of one common share and one common share purchase warrant. Each warrant is exercisable at a price of $4.60 per underlying common share for a period of 4 years from the first closing of the Offering.